The shifting sands of early stage R&D
Paul Overton, Aptuit’s Executive Vice President of business development and marketing, a scientist by background, talks to Jo Shorthouse of Scrip 100 Publication, about the evolving R&D model and how the CRO industry can work creatively on early stage research.
In this article, Paul discusses -
- How the R&D paradigm needs to change in order to deliver more drugs to the market
- If big pharma has been too slow to evolve to the R&D model
- The key hurdles ahead of early stage research